People · Operator
Named in public records as an officer, director or promoter · active 2016–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| LifeMine Therapeutics, Inc. | — | Biotechnology | Series B | $30.1M | $995.2M | 2016 |
Hingge L. Hsu at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Hingge L. Hsu on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gregory L Verdine | 1 | 3 |
| WeiQing L Zhou | 1 | 2 |
| Yanling L. Cao | 1 | 1 |
| Richard L. Klausner | 1 | 1 |
| Wei L. Li | 1 | 1 |
| Krishna L. Yeshwant | 1 | 1 |
| Jim L. Tananbaum | 1 | 1 |
| Edward L. Hu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.